913581-92-7

Usage

Uses

Used in Pharmaceutical Industry:
6,7-dihydrothieno[3,2-d]pyrimidine-2,4-diol is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Chemical Research:
6,7-dihydrothieno[3,2-d]pyrimidine-2,4-diol serves as a subject of study in chemical research, where its properties and reactivity can be explored. Researchers may investigate its potential as a catalyst, its interactions with other molecules, or its use in the formation of new chemical entities.
Used in Material Science:
In the field of material science, 6,7-dihydrothieno[3,2-d]pyrimidine-2,4-diol may be utilized in the development of novel materials with specific properties. Its incorporation into polymers or other materials could lead to advancements in areas such as electronics, sensors, or energy storage.
Used in Biological Studies:
6,7-dihydrothieno[3,2-d]pyrimidine-2,4-diol is used as a research tool in biological studies, where its interaction with biological systems can be examined. It may be employed to investigate its effects on cellular processes, its potential as a therapeutic agent, or its role in understanding disease mechanisms.

InChI:InChI=1/C6H6N2O2S/c9-5-4-3(1-2-11-4)7-6(10)8-5/h1-2H2,(H2,7,8,9,10)

Upstream product

• 4900-98-5 2-ethylsulfanyl-6,7-dihydro-3H-thieno[3,2-d]pyrimidin-4-one 
• 1196101-46-8 3-ureido-4,5-dihydro-thiophene-2-carboxylic acid methyl ester 
• 2689-69-2 methyl tetrahydrothiophen-3-one-2-carboxylate 
• 7400-45-5 dimethyl-3-thiaadipate 
• 4900-98-5 2-(ethylthio)-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one 

Downstream Products

• 74901-69-2 2,4-dichloro-6,7-dihydro-thieno[3,2-d]pyrimidine 
• 1429638-96-9 (S)-1-cyclopropyl-3-(4-(4-(3-methylmorpholino)-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)urea 
• 913582-05-5 3-(2-chloro-6,7-dihydro-thieno[3,2-d]pyrimidin-4-ylamino)-benzoic acid 
• 913578-19-5 {(1S,2S)-2-[2-(4-phenyl-piperazin-1-yl)-6,7-dihydro-thieno[3,2-d]pyrimidin-4-ylamino]-cyclopentyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Development of a Practical Process for the Synthesis of PDE4 Inhibitors

A practical, safe, and efficient process for the synthesis of PDE4 (phosphodiesterase type 4) inhibitors represented by 1 and 2 was developed and demonstrated on a multi-kilogram scale. Key aspects of the process include the regioselective synthesis of dihydrothieno[3,2-d]pyrimidine-2,4-diol 9 and the asymmetric sulfur oxidation of intermediate 11.

NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA

Piperidino-dihydrothienopyrimidine sulfoxides of formula I wherein: Ring A is a 6-membered aromatic ring optionally comprising one or two nitrogen atoms andR is Cl and is located in the para-, meta-, or ortho-position of Ring A,S* is a sulphur atom that represents a chiral center, and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.

SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS

A method of treating diabetes mellitus or a microvascular or macrovascular complication of diabetes mellitus in a patient in need thereof, the method comprising administering to the patient a compound of formula 1 wherein R1, R2, R3, and R4 are as defined in claim 1.

SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS

The invention relates to compounds of formula 1 for their use for the treatment of diabetes mellitus or for the treatment of a microvascular or macrovascular complication of diabetes mellitus wherein R1, R2, R3 and R4 are defined as summarized in claim 1. Further the invention relates to the use of compounds of the above formula 1 for the manufacture of a medicament for the treatment of diabetes mellitus or for the treatment of a microvascular or macrovascular complication of diabetes mellitus.

MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS

The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments

NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA

The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is CI and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center, and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.

SYNTHESIS OF DIHYDROTHIENO[3,2-d]PYRIMIDINE DIOLS AND SIMILAR PYRIMIDINE DIOLS

The present invention relates to an improved process for the preparation of dihydrothieno[3,2-d]pyrimidine diols, and similar pyrimidine diols, that is efficient, high-yielding, and does not require expensive and potentially unstable intermediates. The di

Compounds for the treatment of inflammatory diseases

Dihydrothienopyrimidines of formula 1 and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES

The invention relates to novel dihydrothienopyrimidines of formula (1) as well as pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of ailments or diseases of the respiratory tract, gastrointestinal ailments or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system, or cancer diseases. Also disclosed are pharmaceutical compositions containing the inventive compounds.